Bystolic Drug Companies Noncompete Agreements Antitrust Complaint

July 29, 2020

When it’s time for a “blockbuster” drug’s patent to expire, makers of generics are normally in a hurry to create their own versions. However, the complaint for this antitrust class action alleges that those involved with the drug Bystolic entered into noncompete agreements with potential competitors, to delay the entry of generics into the market. The defendants include AbbVie, Inc., three companies under the Allergan name, and three under the Forest Laboratories name.

Case Event File: Bystolic Drug Companies Noncompete Agreements Antitrust Complaint

Related to: Bystolic Drug Companies Noncompete Agreements Antitrust Class Action